Tumor-associated hepatic arterioles and capillary microvasculature

Tumor-associated hepatic arterioles and capillary microvasculature represent the specialized vascular network that develops to support the growth of primary and metastatic liver tumors, such as hepatocellular carcinoma (HCC). Unlike healthy liver tissue, which receives approximately 75% of its blood supply from the portal vein, malignant liver tumors undergo a process of arterialization, becoming almost exclusively dependent on the hepatic artery and its branches (Source: NIH/NCI, PDQ Cancer Information). This transition is characterized by intense angiogenesis and the capillarization of hepatic sinusoids, where the normally fenestrated endothelium is replaced by a continuous basement membrane, facilitating efficient nutrient delivery to the tumor (Source: PubMed, PMID: 11519058). This vascular compartment is a primary target for both systemic anti-angiogenic therapies and locoregional interventions. Systemic drugs like Sorafenib and Lenvatinib target the molecular drivers of this growth, such as VEGF and PDGF receptors, while locoregional therapies like transarterial chemoembolization (TACE) physically block these vessels to induce tumor ischemia (Source: StatPearls, Hepatocellular Carcinoma, 2023). Because this target is a complex histological structure rather than a single molecule, it is often classified as an anatomical or physiological target in oncology.

Other names

Tumor-associated hepatic microvasculatureHepatic tumor neovasculatureArterialized tumor vesselsCapillarized hepatic sinusoidsTumor-related hepatic arterial supply

Inhibition of pro-angiogenic signaling pathways (VEGFR, PDGFR, FGFR) to disrupt vessel formation and physical occlusion of arterial supply (embolization) to induce tumor ischemia and necrosis.